{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T14:06:57Z","timestamp":1779545217948,"version":"3.53.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,23]]},"DOI":"10.7759\/cureus.109495","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T13:45:52Z","timestamp":1779543952000},"source":"Crossref","is-referenced-by-count":0,"title":["Discordant Radiologic and Biochemical Response With Inflammatory Activity in Metastatic Prostate Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Ivan","family":"Bivolarski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsvetelina","family":"Yordanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher HI","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al.. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016, 34:1402-18. 10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-025-01268-2","article-title":"The role of PSMA PET imaging in prostate cancer: current applications and future directions","volume":"26","author":"Islam R","year":"2025","unstructured":"Islam R, Desai S, Moran M, Golombos DM. The role of PSMA PET imaging in prostate cancer: current applications and future directions. Curr Urol Rep. 2025, 26:46. 10.1007\/s11934-025-01268-2","journal-title":"Curr Urol Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels AM","year":"2008","unstructured":"H\u00f6vels AM, Heesakkers RA, Adang EM, et al.. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008, 63:387-95. 10.1016\/j.crad.2007.05.022","journal-title":"Clin Radiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem G","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B, et al.. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015, 520:353-7. 10.1038\/nature14347","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton AJ","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, et al.. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014, 106:dju124. 10.1093\/jnci\/dju124","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford P","year":"2024","unstructured":"Cornford P, van den Bergh RC, Briers E, et al.. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024, 86:148-63. 10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy","volume":"31","author":"Halabi S","year":"2013","unstructured":"Halabi S, Armstrong AJ, Sartor O, et al.. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013, 31:3944-50. 10.1200\/JCO.2013.50.3201","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3670-z","article-title":"(68)Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler WP","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, et al.. (68)Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017, 44:1014-24. 10.1007\/s00259-017-3670-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis","volume":"77","author":"Perera M","year":"2020","unstructured":"Perera M, Papa N, Roberts M, et al.. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020, 77:403-17. 10.1016\/j.eururo.2019.01.049","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson D","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, et al.. Integrative clinical genomics of advanced prostate cancer. Cell. 2015, 161:1215-28. 10.1016\/j.cell.2015.05.001","journal-title":"Cell"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard G","year":"2016","unstructured":"Attard G, Parker C. Prostate cancer. Lancet. 2016, 387:70-82. 10.1016\/S0140-6736(14)61947-4","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01817-1","article-title":"Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies","volume":"18","author":"Cupp MA","year":"2020","unstructured":"Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020, 18:360. 10.1186\/s12916-020-01817-1","journal-title":"BMC Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher HI","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, et al.. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008, 26:1148-59. 10.1200\/JCO.2007.12.4487","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/482628-discordant-radiologic-and-biochemical-response-with-inflammatory-activity-in-metastatic-prostate-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T13:45:54Z","timestamp":1779543954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/482628-discordant-radiologic-and-biochemical-response-with-inflammatory-activity-in-metastatic-prostate-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.109495","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,23]]}}}